Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Hims & Hers Health, Inc. reported that institutional investor Capital World Investors beneficially owns 14,322,912 shares of its common stock, representing 6.5% of the class, based on 219,270,891 shares believed to be outstanding as of the ownership date.
Capital World Investors reports sole voting power over 14,316,043 shares and sole dispositive power over 14,322,912 shares, with no shared voting or dispositive power. The shares are stated to be acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Hims & Hers Health, Inc.’s Chief Financial Officer, Oluyemi Okupe, reported an option exercise and share sale in Class A Common Stock on February 3, 2026.
He exercised 5,262 stock options at an exercise price of $5.01 per share, then sold 5,262 shares of Class A Common Stock at an average price of $26.4363 per share under a Rule 10b5-1 trading plan adopted on May 21, 2025. After these transactions, he directly owned 91,617 shares of Class A Common Stock and 144,051 stock options, and indirectly held 7,853 shares through the Oluyemi Okupe Separate Property Trust dated September 1, 2021.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported stock option exercises and a share sale. On January 20, 2026, the CFO exercised stock options for 7,317 Class A Common shares at an exercise price of $5.01 per share and for 1,750 shares at $11.53 per share. That same day, 9,067 Class A Common shares were sold at a weighted average price of $30.3423, with actual sale prices ranging from $30.21 to $30.44.
After these transactions, the CFO directly owned 91,617 Class A Common shares and held stock options covering 149,313 and 42,996 shares in two separate option awards. An additional 7,853 shares were held indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021. The filing states that the option exercises and related sales were carried out under a Rule 10b5-1 trading plan adopted on May 21, 2025, which is a pre-arranged program for trading company stock.
Form 144 indicates a planned sale of 27,204 shares of HIMS common stock through Goldman Sachs & Co. LLC on the NYSE, with an aggregate market value of $828,905.88. These shares relate to stock options granted as compensation and acquired via cashless exercise and same-day sale transactions dated 02/24/2022 and 03/01/2023.
The notice lists 219,270,891 common shares outstanding and details prior sales by Oluyemi Okupe over the past three months, including multiple blocks of common stock sold on 11/17/2025, 12/22/2025, and 01/05/2026 with specified share amounts and gross proceeds.
Hims & Hers Health Chief Financial Officer Oluyemi Okupe reported option exercises and a stock sale involving Class A common stock. On January 5, 2026, Okupe exercised stock options for 2,178 shares at $5.01 and 3,808 shares at $11.53 per share, receiving the same number of Class A shares. On the same day, Okupe sold 9,070 shares of Class A common stock at an average price of $33.7875.
The filing states that these option exercises and sales were carried out under a Rule 10b5-1 trading plan adopted on May 21, 2025. After the reported transactions, Okupe directly held 91,617 Class A shares and indirectly held 7,853 additional shares through the Oluyemi Okupe Separate Property Trust dated September 1, 2021.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported a sale of Class A common stock. On 12/22/2025, the reporting person sold 23,090 shares at an average price of $35.7172, with trades executed in a price range of $35.36–$35.88. The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on May 21, 2025, which is designed to systematically execute trades over time.
After this transaction, the reporting person beneficially owns 94,333 shares of Class A common stock directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated 9-1-2021.
HIMS insider Oluyemi Okupe has filed a Rule 144 notice to sell up to 32,160 shares of common stock through Goldman Sachs & Co. LLC. The planned sale has an aggregate market value of $1,127,208, with the shares listed on the NYSE and 219,270,891 shares of this class outstanding. The shares come from equity compensation, including restricted stock units and stock options acquired between February 2022 and December 2025, with some tied to cashless, same-day option exercises.
Over the prior three months, the same seller completed several sales of HIMS common stock, ranging from 11,592 to 85,000 shares per transaction, for gross proceeds between roughly $669,232 and $5,116,923.50. By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Hims & Hers Health, Inc. Chief Operating Officer Michael Chi reported selling 13,750 shares of Class A common stock on 12/17/2025 at $36.71 per share. The transaction was reported with transaction code "S" and was effected under a Rule 10b5-1 trading plan adopted on March 4, 2025.
After this sale, Chi beneficially owns 305,161 shares of Hims & Hers Health, Inc. common stock in direct ownership.
Hims & Hers Health, Inc. director and Chief Policy Officer Deborah M Autor reported selling 7,054 shares of Class A common stock on December 17, 2025 at $36.71 per share. The transaction was filed on Form 4 as a sale of non-derivative securities.
After this sale, she beneficially owned 6,175 shares of Class A common stock, held directly. The filing notes that the sale was effected under a Rule 10b5-1 trading plan adopted on August 11, 2025, indicating the trades followed a pre-established plan.
Hims & Hers Health, Inc. director and Chief Medical Officer Patrick Harrison Carroll reported selling 10,021 shares of Class A common stock on 12/17/2025 at $36.71 per share.
After this transaction, Carroll beneficially owns 169,940 shares of Hims & Hers Class A common stock, held directly. The sale was carried out pursuant to a Rule 10b5-1 trading plan adopted on May 19, 2025.